Author

Gabriel M. Simon

Vividion Therapeutics (United States)ORCID 0000-0002-5960-5536Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

David S. WeinsteiniD· 2 shared Matthew P. PatricelliiD· 2 shared Aaron Nathan SneadiD· 1 shared Aulma R. ParkeriD· 1 shared Benjamin D. HorningiD· 1 shared Brent M. KuenziiD· 1 shared Brian E. NordiniD· 1 shared Christie L. EissleriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

David S. WeinsteinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Allosteric covalent inhibition of cereblon through cryptic cysteine targeting

Zeba Rizvi, Brian E. Nordin, Kent T. Symons, Kristen A. Baltgalvis, David S. Weinstein, Matthew P. Patricelli, Gabriel M. Simon, Jeffery W. Kelly

The paper identifies covalent ligands targeting a cryptic cysteine in CRBN, demonstrating their ability to inhibit neosubstrate degradation by trapping CRBN in an inactive conformation.

bioRxiv · Oct 15, 2026 · PreprintBiochemistry

Suppression of NRF2-dependent cancer growth by a covalent allosteric molecular glue

Nilotpal Roy, Tine L Wyseure, I‐Chung Lo, Justine Lu, Christie L. Eissler, Steffen M. Bernard, Ilah Bok, Aaron Nathan Snead, Aulma R. Parker, U‐Ging Lo, Jason C. Green, Jordon M. Inloes, Sarah R. Jacinto, Brent M. Kuenzi, Marie Pariollaud, , Matthew P. Patricelli

This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.

Cancer Discovery · Dec 19, 2025Peer-reviewedCancer Biology